No headlines found.
Globe Newswire (Mon, 3-Nov 8:00 AM ET)
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
Globe Newswire (Tue, 28-Oct 8:00 AM ET)
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
Globe Newswire (Tue, 7-Oct 8:00 AM ET)
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Nautilus Biotechnology trades on the NASDAQ stock market under the symbol NAUT.
As of January 7, 2026, NAUT stock price climbed to $2.10 with 281,446 million shares trading.
NAUT has a beta of 1.84, meaning it tends to be more sensitive to market movements. NAUT has a correlation of 0.19 to the broad based SPY ETF.
NAUT has a market cap of $265.24 million. This is considered a Small Cap stock.
In the last 3 years, NAUT traded as high as $4.65 and as low as $.62.
The top ETF exchange traded funds that NAUT belongs to (by Net Assets): VTI, VXF, DFAC, DFAS, MSSM.
NAUT has outperformed the market in the last year with a price return of +20.7% while the SPY ETF gained +17.7%. NAUT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +142.7% and +7.7%, respectively, while the SPY returned +3.6% and +0.8%, respectively.
NAUT support price is $1.78 and resistance is $1.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NAUT shares will trade within this expected range on the day.